e-therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
e-therapeutics has a total shareholder equity of £22.0M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £25.0M and £3.0M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£20.67m |
| Equity | UK£21.99m |
| Total liabilities | UK£2.98m |
| Total assets | UK£24.97m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ETXP.F's short term assets (£23.6M) exceed its short term liabilities (£2.7M).
Long Term Liabilities: ETXP.F's short term assets (£23.6M) exceed its long term liabilities (£317.0K).
Debt to Equity History and Analysis
Debt Level: ETXP.F is debt free.
Reducing Debt: ETXP.F has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ETXP.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ETXP.F has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 23.4% each year.